Kabir Mody

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.3K citations · Full text

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2022 · 390 citations

First-line Therapy, Psychotropic Medication, Pathology +25

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Jason Willis, Martina I. Lefterova, Alexander Artyomenko et al. · Clinical Cancer Research · 2019 · 230 citations

Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution

John Stauffer, Alessandro Coppola, Diego Villacreses et al. · Surgical Endoscopy · 2016 · 154 citations

Laparoscopy, Surgical Oncology, Pancreatic Cancer +7